Substance / Medication

Cinacalcet hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Change in coronary artery calcification score due to cinacalcet hydrochloride administration.
Tsuruta Yoshinari, Ohbayashi Takaaki, Fujii Mikiko et al. · Ther Apher Dial · 2008
PMID: 19032525RCT
Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akiba Takashi, Akizawa Tadao, Tsukamoto Yusuke et al. · Ther Apher Dial · 2008
PMID: 18387159RCT
Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.
Nakashima Daisuke, Takama Hirotaka, Ogasawara Yuko et al. · J Clin Pharmacol · 2007
PMID: 17652181RCT
Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Takeuchi Yasuhiro, Takahashi Shunsuke, Miura Daishu et al. · J Bone Miner Metab · 2017
PMID: 27873072Trial
Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.
Harris Robert Z, Salfi Margaret, Sullivan John T et al. · Clin Pharmacokinet · 2007
PMID: 17518508Trial
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.
Silverberg S J, Rubin M R, Faiman C et al. · J Clin Endocrinol Metab · 2007
PMID: 17666472Trial
Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
Chertow Glenn M, Blumenthal Samuel, Turner Stewart et al. · Clin J Am Soc Nephrol · 2006
PMID: 17699221Trial
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
Charytan Chaim, Coburn Jack W, Chonchol Michel et al. · Am J Kidney Dis · 2005
PMID: 15983958Trial
Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.
Peacock Munro, Bilezikian John P, Klassen Preston S et al. · J Clin Endocrinol Metab · 2005
PMID: 15522938Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cinacalcet hydrochloride (substance)
SNOMED CT
426512007
UMLS CUI
C1260199

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.